about
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisManagement of myelofibrosis: JAK inhibition and beyond.Stereoretentive Olefin Metathesis: An Avenue to Kinetic Selectivity.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer.Protein kinase inhibitors for acute leukemia.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.
P2860
Q33434284-5D824625-17F0-41E2-A248-FEAB09DA2EE7Q39232415-8EAE740B-28DD-4E6B-87E4-5EABCA3305CDQ39362526-11D3B3F7-0936-4602-AF82-0FE57012B1DAQ47133172-366FCF8F-DA22-4269-B0C8-6EA3BE2E2146Q47233779-311BE757-F672-4F2A-8E85-F7DA37F6B047Q49873905-6D1D59AA-9BC3-405D-91EC-07A9F7D9307DQ52813540-796EC8FB-2D49-48B9-B76D-636BDDD7AA4F
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A comprehensive review of pacritinib in myelofibrosis.
@en
type
label
A comprehensive review of pacritinib in myelofibrosis.
@en
prefLabel
A comprehensive review of pacritinib in myelofibrosis.
@en
P2860
P356
P1433
P1476
A comprehensive review of pacritinib in myelofibrosis.
@en
P2093
Rami S Komrokji
P2860
P304
P356
10.2217/FON.15.200
P407
P577
2015-09-14T00:00:00Z